What can we help you with today?
🔗 CustomizeMedical Overview of Charcot-Marie-Tooth Disease, Demyelinating, Type 1G
Sources citedA rare autosomal dominant hereditary demyelinating motor and sensory neuropathy characterized by progressive distal muscle weakness and atrophy, distal sensory impairment, and decreased or absent reflexes in the affected limbs, with an onset in the first or second decade of life. Median motor nerve conduction velocities are typically less than 38 m/s. Patients often have foot deformities. Sural nerve biopsy shows decrease in myelinated fibers, myelin abnormalities, and onion bulb formation. Fatty replacement of muscle tissue predominantly affects the anterior and lateral compartment of the lower legs.
Classification & codes: GARD 0017851 · Orphanet ORPHA:476394 · OMIM 618279 · ICD-10 G60.0
Sources: GARD (NIH/NCATS), Orphanet · last reviewed 2026. Educational only — not medical advice.
News & Updates
ALYFTREK shows positive Phase 3 results in children ages 2–5
Vertex plans global regulatory submissions for this pediatric age group in the first half of 2026.
Airway clearance routines that actually work for teens
3 open trials match this profile
Locations in NC, FL and GA.
Charcot-Marie-Tooth Disease, Demyelinating, Type 1G Family Conference
Illustrative example event · location TBD
Care & management overview — Charcot-Marie-Tooth Disease, Demyelinating, Type 1G
Educational programming; see the cited sources on this hub.
Charcot-Marie-Tooth Disease, Demyelinating, Type 1G News & Developments
The latest Charcot-Marie-Tooth Disease, Demyelinating, Type 1G research, news and registered trials — live from public sources. Each link opens the source directly; nothing here is auto-summarized or invented.
Recruiting trials
View all →Find a Charcot-Marie-Tooth Disease, Demyelinating, Type 1G Specialist Near You
Sample results — illustrative only. A real version would search the NPPES provider registry and CFF-certified centers by actual distance from your ZIP.
Treatment & Daily Living
Medical care plus the everyday therapies and supports relevant to Charcot-Marie-Tooth Disease, Demyelinating, Type 1G. Treatment is individualized — ask your specialist about the medications, procedures and therapies. Browse medications →
Media Center
News, podcasts, books & research for Charcot-Marie-Tooth Disease, Demyelinating, Type 1G — real coverage, links out, never re-hosted.
Audience Guides
Plain-language guidance for the people around someone with Charcot-Marie-Tooth Disease, Demyelinating, Type 1G — how to understand it and talk about it. AI-generated for communication, not medical advice; always confirm specifics with a clinician.
Companies Developing Treatments
Biopharma companies with registered trials for Charcot-Marie-Tooth Disease, Demyelinating, Type 1G — from ClinicalTrials.gov. Informational, not an endorsement, and not every program is in trials.
Preferences only — saved to your account, never shared or sold. No PHI. Sources: GARD (NIH/NCATS), Orphanet.
Tools
Every institution behind the faculty, with their affiliated experts.
Plain-language tools
For clinicians, nonprofits & industry partners.
Translates any dense medical text — papers, lab results, visit notes, jargon — into plain language.
Live on tomekohealth.com — not a demo mock-up.
Research Collaboration & Matching
Live on tomekohealth.com — not a demo mock-up.
Mental Health Toolkit
Sources citedCoping strategies, how to find a a specialist therapist, and mental-health resources built for the ups and downs of living with Charcot-Marie-Tooth Disease, Demyelinating, Type 1G — for patients and caregivers alike.
Preferences only — saved to your account, never shared or sold. No PHI. Sources: GARD (NIH/NCATS), Orphanet.
Grand Rounds & Accredited Education
Open Questions
Ask the community →Anyone can ask. Sign in to answer. Peer support — not medical advice, and no PHI.
Survey
Reflect on how you are doing — anonymous, with only de-identified group averages shown.
Community & Support Groups
For people living with Charcot-Marie-Tooth Disease, Demyelinating, Type 1G. Peer support, not medical advice; no PHI.
For caregivers and family navigating Charcot-Marie-Tooth Disease, Demyelinating, Type 1G.
Recent From the Community
Certified Centers of Excellence
CFF networkCare centers and specialists for Charcot-Marie-Tooth Disease, Demyelinating, Type 1G, from Tomeko’s verified provider directory (CMS NPPES).
Representative CFF centers — the official CFF directory has the complete, current list.
Nonprofits & Foundations
Grants & Financial Help
Representative programs — illustrative only. Eligibility and availability vary; not a guarantee of assistance.
Patient & Family Guides
Sources citedAn annual snapshot of Charcot-Marie-Tooth Disease, Demyelinating, Type 1G research, treatment access and outcomes, written in plain language for patients and families.
Practical starting points and things to plan for in the first year after diagnosis.
Step-by-step guidance, what to expect, and a sample daily routine.
Disclosure, accommodations, insurance transitions and workplace planning for teens and young adults with Charcot-Marie-Tooth Disease, Demyelinating, Type 1G.
Sources: GARD (NIH/NCATS), Orphanet · last reviewed 2026. Educational only — not medical advice.